证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-028 登录新浪财经APP 搜索【信披】查看更多考评等级 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 是否以公积金转增股本 □是 √否 公司经本次董事会审议通过的利润分配预案为：以未来实施分配方案时股权登记日的总股本为基数，向 全体股东每10股派发现金红利2元（含税），送红股0股（含税），不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 ■ 2、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √是 □否 追溯调整或重述原因 会计政策变更 ■ □适用 √不适用 二、公司基本情况 1、公司简介 会计政策变更的原因及会计差错更正的情况 《企业会计准则解释第18号》（财会[2024]24号）"关于浮动收费法下作为基础项目持有的投资性房地 产的后续计量"、"关于不 ...

Summary of Yuyue Medical Conference Call Company Overview - Yuyue Medical focuses on home medical devices, with core businesses in respiratory oxygen, blood glucose and POCT, home health monitoring, and clinical rehabilitation [4][7] - The company is actively incubating its emergency business, particularly in the AED (Automated External Defibrillator) sector, which shows strong growth potential [4][18] Core Business Performance Respiratory Oxygen - Revenue in 2024 is projected to be 2.6 billion RMB, with fluctuations due to changes in public demand [8] - The market for OSA (Obstructive Sleep Apnea) and COPD (Chronic Obstructive Pulmonary Disease) patients in China is underdiagnosed compared to the US, indicating significant market expansion potential [9] - Yuyue holds a market share of 23.4% in the oxygen machine sector, maintaining the leading position [9] Blood Glucose and POCT - Revenue in this sector is expected to reach 1 billion RMB in 2024, reflecting a 40% year-on-year growth [10] - The large diabetic population in China, estimated at 140 million as of 2021, provides a substantial market for CGM (Continuous Glucose Monitoring) systems [10][13] - Yuyue entered the CGM market after acquiring Zhejiang Kailite in 2021, with its latest product, ANYTY5, receiving approval in April 2025 [14][15] Home Health Monitoring - The electronic blood pressure monitor market is projected to reach 6 billion RMB by 2025, with Yuyue holding an 11% market share [16] - The company aims to capitalize on the low awareness and treatment rates of hypertension in China, where approximately 245 million people are affected [16] Clinical Instruments and Rehabilitation - This segment is expected to generate 2.09 billion RMB in revenue in 2024, showing stable growth [17] - The company is focusing on developing new products and expanding its customer base to enhance brand strength [17] Incubation Business - The AED business is rapidly growing, with total revenue of 240 million RMB in 2024, a 34% increase year-on-year, and a market share of 7.8% [19] - The total procurement scale for AEDs in China reached 600 million RMB in 2024, with a year-on-year growth of 85% [19] Sales Channels and Strategy - Yuyue has a comprehensive sales strategy, with online sales accounting for 38% of total revenue in Q1 2025 [6][20] - The company achieved 950 million RMB in overseas revenue in 2024, growing at 30% [6] - A strategic partnership with Innotek aims to enhance sales channels in Europe and the US [6][20] Future Outlook - Earnings per share (EPS) projections for 2025, 2026, and 2027 are 2.01 RMB, 2.36 RMB, and 2.78 RMB, respectively [21] - The company is rated as a "buy" based on a 24x PE valuation for 2025 [21]

Group 1 - The Chengdu Qingyang District Health Bureau announced the procurement results for automatic external defibrillators (AEDs) for public places in 2025, with Sichuan Jiuzhoutong Medical Equipment Supply Chain Management Co., Ltd. winning the bid [1][2] - The total bid amount for the procurement project is 3,686,320.00 yuan, with a total score of 99.80 in the evaluation [3][2] - The company will supply 176 sets of Mindray's AEDs at a unit price of 16,980.00 yuan and 176 sets of Meisen's intelligent AED cases at a unit price of 3,965.00 yuan [3][1] Group 2 - Sichuan Jiuzhoutong Medical Equipment Supply Chain Management Co., Ltd. was established in 2023 with a registered capital of 60 million yuan and is a subsidiary of Jiuzhoutong Pharmaceutical Group Co., Ltd. [4] - The actual controller of the company holds a voting power of 51% and a total shareholding ratio of 9.7482% [5]

Core Viewpoint - The article emphasizes the importance of "small and flexible" legislation that addresses specific social issues and meets the urgent needs of the public, ensuring that laws are practical and effective in solving real problems [1][2][3][4] Group 1: Legislative Trends - There is a growing trend of "small and flexible" legislation, particularly in the social welfare sector, which allows for quick responses to pressing issues [1][2] - Local regulations, such as the decision in Yancheng to equip public places with AEDs, demonstrate the effectiveness of targeted legislation in addressing specific community needs [1] - The focus on problem-oriented legislation enhances the relevance, applicability, and operability of local laws [2] Group 2: Implementation and Effectiveness - The "small and flexible" legislative approach is characterized by its ability to be practical, assessable, and implementable, as seen in the safety management regulations for rental factories in Changzhou [2][3] - Legislation is not an endpoint; its effectiveness must be evaluated through practical application and public feedback [3] - The quality of legislation remains a priority, ensuring that necessary research and procedural integrity are maintained despite the concise nature of the laws [3] Group 3: Public Engagement and Trust - The foundation of the rule of law lies in its responsiveness to public concerns, fostering broad consensus during the legislative process [4] - Legislation should reflect the interests and needs of the people, enhancing their sense of security, happiness, and well-being [4]

Core Viewpoint - The training conducted by Dongying Airport and the Red Cross Society of Dongying aims to enhance the emergency rescue capabilities of frontline employees, thereby strengthening passenger safety measures [1][4]. Group 1: Training Overview - The training involved over 80 employees from various frontline positions, including customer service, security, and firefighting [1]. - The training was delivered by a team of emergency rescue instructors from the Red Cross, covering CPR basics, AED operation, and emergency response procedures [3]. Group 2: Training Content - Theoretical instruction included common causes of cardiac arrest, clinical manifestations, and rescue principles, emphasizing the critical "golden four minutes" for saving lives [3]. - Simulation demonstrations utilized human models to illustrate the standard CPR process, including awareness assessment, breathing checks, chest compressions, and artificial respiration [3]. Group 3: Practical Training - Participants engaged in hands-on practice with one-on-one guidance from instructors to ensure proper technique and build confidence in their rescue abilities [4]. - The training is part of a broader initiative to enhance the airport's emergency response system and promote a culture of safety [4].

Investment Rating - The report provides a positive outlook for the pharmaceutical and biotechnology sector, indicating a strong performance compared to the broader market indices [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.27%, outperforming the Wind All A index (0.72%) and the CSI 300 index (1.12%) [3][8]. - Key sub-sectors such as raw materials (3.79%), in vitro diagnostics (2.25%), and vaccines (1.98%) showed significant gains, while offline pharmacies (-1.24%) and blood products (-0.03%) experienced declines [3][9]. - The report highlights the competitive advantage of tirzepatide over semaglutide in weight loss efficacy, with tirzepatide achieving a 1.47 times greater relative weight reduction and a 64.6% participant rate achieving ≥15% weight loss compared to 40.1% for semaglutide [3][12]. - COVID-19 is entering a phase of periodic outbreaks, with increasing infection rates reported in various regions, prompting recommendations for booster vaccinations among older populations [3][11]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from May 12 to May 16 showed a 1.27% increase, with raw materials leading the gains at 3.79% [8]. - Notable individual stock movements included a significant rise in COVID-19 related stocks like Tuoxin Pharmaceutical, which surged by 45% [11]. Industry News and Key Company Announcements - Recent monitoring data from health authorities in Hong Kong and Singapore indicate a rise in COVID-19 cases, suggesting a potential peak in infections soon [11][13]. - Eli Lilly's tirzepatide clinical trial results demonstrate its superiority over Novo Nordisk's semaglutide in weight loss, indicating a promising market opportunity for obesity treatments [12][13]. - Several companies, including North Sea Kangcheng and Hengrui, have made significant announcements regarding new drug approvals and clinical trials, reflecting ongoing innovation in the sector [13][14].

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]

Market Overview - On May 15, major market indices collectively declined, with the Shanghai Composite Index falling by 0.68% and the ChiNext Index dropping nearly 2% [1] - The total trading volume in A-shares reached 1.19 trillion yuan, with over 1,400 stocks closing higher, including 78 stocks hitting the daily limit [1] Sector Performance - The beauty and personal care sector led the gains, closing up 3.68%, with stocks like Qingsong Co., Huaye Fragrance, and Jieya Co. hitting the daily limit [1] - The port and shipping sector experienced a pullback after an initial rise, with stocks such as Nanjing Port and Ningbo Maritime continuing to hit the daily limit [1] - The synthetic biology concept index rose over 2%, with 10 stocks hitting the daily limit, including Chuaning Biology and Meinong Biology [1] Historical Highs - A total of 28 stocks reached historical closing highs, with the beauty and personal care, banking, and machinery sectors showing significant concentration [2] - The average increase for stocks that reached historical highs was 6.87%, with notable gainers including Babi Co., Dengkang Oral, and Ruoyuchen [2] Institutional Trading - On May 15, 14 stocks faced net selling by institutions exceeding 10 million yuan, with Youfu Co. leading the sell-off at 146 million yuan [4] - Only 8 stocks saw net buying from institutions, with Aerospace Nanhu and Yuzhong Three Gorges A receiving over 10 million yuan in net purchases [4] Northbound Capital Flow - Northbound capital saw net buying in 5 stocks, with Jilin Chemical Fiber leading at 33.01 million yuan, followed by Jingyun Tong at 28.59 million yuan [6] - Aerospace Nanhu experienced the highest net selling among northbound funds, amounting to 50.41 million yuan [6] Company Announcements - Feilong Co. received a project designation notice from a well-known domestic automotive brand, becoming a supplier for a thermal management module [7] - Yuyue Medical's automatic external defibrillator (AED) product obtained EU MDR certification [8] - Heng Rui Pharmaceutical completed a share repurchase of 12.90 million shares, accounting for 0.2% of its total share capital, with a total transaction amount of 601 million yuan [8]

Group 1: Hainan Airlines - Hainan Airlines reported a 10.33% year-on-year increase in revenue passenger kilometers for April [1] - The group's passenger capacity input increased by 10.32% year-on-year [1] - Cargo and mail volume increased by 23.20% year-on-year, with cargo mail revenue ton-kilometers up by 41.04% [1] Group 2: Heng Rui Medicine - Heng Rui Medicine completed a share buyback, repurchasing 12.9051 million shares for a total of 601 million yuan [2] - The shares repurchased represent 0.2% of the company's total share capital, with an average buyback price of approximately 46.59 yuan per share [2] Group 3: China Shenhua - China Shenhua's coal sales volume in April decreased by 4% year-on-year, totaling 35.6 million tons [6] - The company's total electricity generation fell by 9.9% year-on-year [6] Group 4: China National Aviation - China National Aviation reported an 8.6% year-on-year increase in passenger turnover for April [8] - The average passenger load factor reached 81.3%, up 2.5 percentage points year-on-year [8] Group 5: Yuyue Medical - Yuyue Medical's subsidiary received EU MDR certification for its automated external defibrillator (AED) product [9] Group 6: Hubei Yihua - Hubei Yihua's controlling shareholder plans to increase its stake in the company by 200 million to 400 million yuan [12] Group 7: Other Companies - Chengdi Xiangjiang signed a contract for a data center project with a total value of 1.632 billion yuan [3] - Jingyuan Environmental Protection's subsidiary signed a contract for a computing cluster construction project worth 365 million yuan [4]

Group 1 - Yuyue Medical (002223) announced that its subsidiary Metrax GmbH has received CE certification for its automated external defibrillator (AED) in compliance with the EU Medical Devices Regulation (EU) 2017/745 [1] - The CE certificate number is G700237870039Rev.00, and it is valid from May 12, 2025, to May 11, 2030 [1] - The device is designed for suspected sudden cardiac arrest situations, guiding operators to initiate resuscitation, analyze the patient's electrocardiogram (ECG), and provide defibrillation treatment when a shockable rhythm is detected [1]